Scotland approves MS drug that was rejected in England and WalesBMJ 2021; 372 doi: https://doi.org/10.1136/bmj.n391 (Published 09 February 2021) Cite this as: BMJ 2021;372:n391
- Bryan Christie
- Edinburgh, UK
A drug that can reduce the number of relapses suffered by people with multiple sclerosis (MS) has been approved for use in Scotland despite a provisional decision to reject it in England and Wales.
Ozanimod (Zeposia) is a daily tablet that has been shown in a two year clinical trial to reduce relapses by around 38% compared with an existing treatment, injectable β …